Lucentis Receives Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The BLA for Genentech's wet age-related macular degeneration therapy Lucentis (ranibizumab) has been granted six-month priority review by FDA. The user fee date has been set for June 29, 2006
You may also be interested in...
Genentech Plans Lucentis Launch Within 72 Hours Of Approval
Genentech intends for its pending neovascular wet age-related macular degeneration product Lucentis (ranibizumab) to be available within three days of its approval
Genentech Plans Lucentis Launch Within 72 Hours Of Approval
Genentech intends for its pending neovascular wet age-related macular degeneration product Lucentis (ranibizumab) to be available within three days of its approval
Macugen U.S. Sales Could Reach Over $200 Mil. In “Choppy” 2006, OSI Says
Launch of Genentech’s pending macular degeneration competitor Lucentis and off-label use of Avastin are factors in Macugen sales projection.